NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates

分组1 - NovoCure reported a quarterly loss of $0.22 per share, better than the Zacks Consensus Estimate of a loss of $0.41, and improved from a loss of $0.61 per share a year ago, resulting in an earnings surprise of +46.01% [1] - The company achieved revenues of $174.35 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.83% and increasing from $161.27 million year-over-year [2] - NovoCure has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has gained approximately 15.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.5% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.58 for the coming quarter and -$1.62 for the current fiscal year [4][7] - The Zacks Industry Rank places the Medical - Biomedical and Genetics sector in the top 36% of over 250 Zacks industries, suggesting a favorable industry outlook [8]